one8zero8 LLC Acquires Shares of 883 Becton, Dickinson and Company (NYSE:BDX)

by · The Markets Daily

one8zero8 LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 883 shares of the medical instruments supplier’s stock, valued at approximately $202,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $27,000. REAP Financial Group LLC increased its stake in shares of Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 55 shares in the last quarter. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $29,000. Cornerstone Planning Group LLC increased its stake in shares of Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 99 shares in the last quarter. Finally, Nexus Investment Management ULC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $34,000. 86.97% of the stock is owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the firm’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president owned 4,575 shares in the company, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $185.52 on Monday. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The stock has a market cap of $53.17 billion, a P/E ratio of 35.40, a price-to-earnings-growth ratio of 1.40 and a beta of 0.25. The stock’s 50-day moving average price is $174.31 and its two-hundred day moving average price is $202.31.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The firm had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same quarter last year, the business earned $3.17 earnings per share. The company’s revenue was up 4.5% compared to the same quarter last year. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.24%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 79.39%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BDX. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Barclays lowered their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research report on Tuesday, June 3rd. Bank of America lowered Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price objective for the company. in a research report on Thursday, May 1st. Piper Sandler lowered Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $260.00 to $185.00 in a research report on Friday, May 2nd. Finally, Wells Fargo & Company lowered Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 1st. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average price target of $219.22.

Check Out Our Latest Research Report on Becton, Dickinson and Company

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).